Magné N - Search Results

1

Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer.

Pivot X, Magné N, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Bensadoun RJ, Demard F, Schneider M, Milano G. Pivot X, et al. Among authors: magne n. Oral Oncol. 2005 Mar;41(3):320-7. doi: 10.1016/j.oraloncology.2004.09.011. Oral Oncol. 2005. PMID: 15743695

2

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

Etienne MC, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento JL, Francoual M, Formento P, Renée N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G. Etienne MC, et al. Among authors: magne n. J Clin Oncol. 2002 Jun 15;20(12):2832-43. doi: 10.1200/JCO.2002.09.091. J Clin Oncol. 2002. PMID: 12065560 Clinical Trial.

3

Impact of glycosylation on the effect of cytokines. A special focus on oncology.

Chamorey AL, Magné N, Pivot X, Milano G. Chamorey AL, et al. Among authors: magne n. Eur Cytokine Netw. 2002 Apr-Jun;13(2):154-60. Eur Cytokine Netw. 2002. PMID: 12101071 Free article. Review.

4

[Brachial fluoroscopically guided implantation of venous port devices in oncology patients].

Marcy PY, Magné N, Bailet C, Gallard JC, Valenza B, Schneider M, Demard F, Bentolila F. Marcy PY, et al. Among authors: magne n. Bull Cancer. 2002 Jul-Aug;89(7-8):707-12. Bull Cancer. 2002. PMID: 12206984 Free article. French.

5

The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer.

Ferrero JM, Chamorey E, Magné N, Leccia F, Largillier R, Namer M, Milano G. Ferrero JM, et al. Among authors: magne n. Cancer Chemother Pharmacol. 2002 Dec;50(6):459-64. doi: 10.1007/s00280-002-0519-2. Epub 2002 Sep 19. Cancer Chemother Pharmacol. 2002. PMID: 12451472 Clinical Trial.

6

Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status.

Magné N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, Lagrange JL, Milano G. Magné N, et al. Oncology. 2003;64(3):280-7. doi: 10.1159/000069308. Oncology. 2003. PMID: 12697970

7

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renée N, Marchetti S, Etienne MC, Milano G. Magné N, et al. Clin Cancer Res. 2003 Oct 15;9(13):4735-42. Clin Cancer Res. 2003. PMID: 14581344

8

[Pharmacological consequences of the targeting of epidermal growth factor receptor].

Milano G, Magné N. Milano G, et al. Among authors: magne n. Bull Cancer. 2003 Nov;90 Spec No:S197-201. Bull Cancer. 2003. PMID: 14763140 Free article. Review. French.

9

Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.

Formento P, Hannoun-Levi JM, Fischel JL, Magné N, Etienne-Grimaldi MC, Milano G. Formento P, et al. Among authors: magne n. Eur J Cancer. 2004 Dec;40(18):2837-44. doi: 10.1016/j.ejca.2004.07.033. Eur J Cancer. 2004. PMID: 15571968

10

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G. Etienne MC, et al. Among authors: magne n. Pharmacogenetics. 2004 Dec;14(12):785-92. doi: 10.1097/00008571-200412000-00001. Pharmacogenetics. 2004. PMID: 15608557

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

480 results

Search Page

Filters